MedTrace Logo

CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma

NCT02319486 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2015-03-30

Study results available
· View outcomes & findings →

Summary

This study will evaluate a uniform chemotherapy protocol for nonmetastatic extraocular retinoblastoma

Conditions

  • Retinoblastoma

Interventions

DRUG

carboplatin periocular injection

chemotherapy together with/without 20mg/2ml carboplatin periocular injection

DRUG

CEV chemotherapy

vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Huasheng Yang, M.D, PHD · Zhongshan Ophthalmic Center, Sun Yat-sen University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2014-04-30
Completion
2014-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02319486 on ClinicalTrials.gov